Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3417194 | 0.86 | PRMT5 (0.49) | GSK3AGSK3BAAK1DGAT1PDGFRB | |
| SCHEMBL3450362 | 0.79 | GSK3A (0.42) | GSK3AGSK3BAAK1DGAT1PDGFRB | |
| SCHEMBL3516528 | 0.76 | GSK3A (0.45) | GSK3AGSK3BAAK1DGAT1PDGFRB | |
| SCHEMBL3792127 | 0.76 | DGAT1 (0.43) | GSK3AGSK3BDGAT1PDGFRBKDR | |
| SCHEMBL17379073 | 0.76 | PRMT5 (0.50) | GSK3AGSK3BAAK1DGAT1PDGFRB | |
| SCHEMBL3027524 | 0.75 | PDGFRB (0.41) | GSK3AGSK3BAAK1DGAT1PDGFRB | |
| SCHEMBL18317561 | 0.74 | GSK3A (0.39) | GSK3AGSK3BAAK1DGAT1PDGFRB | |
| SCHEMBL3676643 | 0.73 | ALPL (0.46) | GSK3AGSK3BAAK1DGAT1PDGFRB | |
| SCHEMBL462679 | 0.73 | AAK1 (0.47) | GSK3AGSK3BAAK1DGAT1PDGFRB | |
| SCHEMBL19915217 | 0.73 | GSK3A (0.46) | GSK3AGSK3BAAK1DGAT1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | GPR119, NR3C1, INSR | GSK3A 1695/4885GSK3B 2253/4885AAK1 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.